{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:30:38Z","timestamp":1776353438583,"version":"3.51.2"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jocn.2021.05.004","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T11:15:40Z","timestamp":1622114140000},"page":"422-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparison of the efficacy and safety of levetiracetam and phenytoin in the treatment of established status epilepticus: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"89","author":[{"given":"Li","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Zhe","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Hui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jocn.2021.05.004_b0005","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/adc.2006.107516","article-title":"Outcome of convulsive status epilepticus: a review","volume":"92","author":"Novorol","year":"2007","journal-title":"Arch Dis Child"},{"issue":"6","key":"10.1016\/j.jocn.2021.05.004_b0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","article-title":"Status epilepticus in adults","volume":"14","author":"Betjemann","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2021.05.004_b0015","doi-asserted-by":"crossref","first-page":"a022830","DOI":"10.1101\/cshperspect.a022830","article-title":"Status epilepticus","volume":"6","author":"Seinfeld","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.jocn.2021.05.004_b0020","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MOP.0000000000000825","article-title":"Long-term outcomes after childhood convulsive status epilepticus","volume":"31","author":"Pujar","year":"2019","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"10.1016\/j.jocn.2021.05.004_b0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S2352-4642(17)30174-8","article-title":"Long-term prognosis after childhood convulsive status epilepticus: a prospective cohort study","volume":"2","author":"Pujar","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"10.1016\/j.jocn.2021.05.004_b0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.jocn.2021.05.004_b0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/B978-0-444-63600-3.00009-X","article-title":"Management of status epilepticus","volume":"140","author":"Pichler","year":"2017","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.jocn.2021.05.004_b0040","doi-asserted-by":"crossref","unstructured":"McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2018;1(1):CD001905. DOI:10.1002\/14651858.CD001905.pub3.","DOI":"10.1002\/14651858.CD001905.pub3"},{"issue":"2","key":"10.1016\/j.jocn.2021.05.004_b0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4037\/ccn2016892","article-title":"Status epilepticus in adults: a review of diagnosis and treatment","volume":"36","author":"Lawson","year":"2016","journal-title":"Crit Care Nurse"},{"key":"10.1016\/j.jocn.2021.05.004_b0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2017.02.015","article-title":"Challenges in the treatment of convulsive status epilepticus","volume":"47","author":"Zaccara","year":"2017","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.jocn.2021.05.004_b0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/archneurpsyc.1958.02340020016003","article-title":"Use of parenteral diphenylhydantoin (dilantin) sodium in control of status epilepticus","volume":"79","author":"Carter","year":"1958","journal-title":"AMA Arch Neurol Psychiatry"},{"issue":"6","key":"10.1016\/j.jocn.2021.05.004_b0060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1212\/wnl.18.6.513","article-title":"Intravenous diphenylhydantoin in treatment of acute repetitive seizures","volume":"18","author":"Wallis","year":"1968","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jocn.2021.05.004_b0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/ene.13560","article-title":"A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus","volume":"25","author":"Brigo","year":"2018","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2021.05.004_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit Care"},{"issue":"3","key":"10.1016\/j.jocn.2021.05.004_b0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.seizure.2013.12.007","article-title":"The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies","volume":"23","author":"Yasiry","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.jocn.2021.05.004_b0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yebeh.2016.09.030","article-title":"Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus","volume":"64","author":"Brigo","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"10231","key":"10.1016\/j.jocn.2021.05.004_b0085","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial","volume":"395","author":"Chamberlain","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jocn.2021.05.004_b0090","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.jocn.2021.05.004_b0095","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.BMJ. 2011;343:d5928. DOI:10.1136\/bmj.d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"10.1016\/j.jocn.2021.05.004_b0100","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page MJ, et al.Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.Cochrane Database Syst Rev. 2019;10:ED000142. DOI:10.1002\/14651858.ED000142.","DOI":"10.1002\/14651858.ED000142"},{"issue":"3","key":"10.1016\/j.jocn.2021.05.004_b0105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13312-020-1755-4","article-title":"Comparison of phenytoin, valproate and levetiracetam in pediatric convulsive status epilepticus: a randomized double-blind controlled clinical trial","volume":"57","author":"Vignesh","year":"2020","journal-title":"Indian Pediatr."},{"issue":"10","key":"10.1016\/j.jocn.2021.05.004_b0110","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.4103\/jfmpc.jfmpc_750_19","article-title":"Levetiracetam versus phenytoin in children with status epilepticus","volume":"8","author":"Wani","year":"2019","journal-title":"J Family Med Prim Care"},{"issue":"22","key":"10.1016\/j.jocn.2021.05.004_b0115","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jocn.2021.05.004_b0120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.17511\/ijpr.2018.i04.13","article-title":"Randomized controlled trial of levetiracetam versus fosphenytoin for convulsive status epilepticus in children","volume":"5","author":"Senthilkumar","year":"2018","journal-title":"Int J Pediatr Res"},{"issue":"10186","key":"10.1016\/j.jocn.2021.05.004_b0125","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial","volume":"393","author":"Dalziel","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jocn.2021.05.004_b0130","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3988\/jcn.2019.15.4.468","article-title":"Clinical efficacy and safety of injectable levetiracetam versus phenytoin as second-line therapy in the management of generalized convulsive status epilepticus in children: an open-label randomized controlled trial","volume":"15","author":"Noureen","year":"2019","journal-title":"J Clin Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2021.05.004_b0135","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12098-020-03221-2","article-title":"Clinical effectiveness of levetiracetam compared to fosphenytoin in the treatment of benzodiazepine refractory convulsive status epilepticus","volume":"87","author":"Nalisetty","year":"2020","journal-title":"Indian J Pediatr"},{"issue":"2","key":"10.1016\/j.jocn.2021.05.004_b0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/JPN.JPN_126_17","article-title":"IV Levetiracetam versus IV phenytoin in childhood seizures: a randomized controlled trial","volume":"13","author":"Singh","year":"2018","journal-title":"J Pediatr Neurosci"},{"issue":"10186","key":"10.1016\/j.jocn.2021.05.004_b0145","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2021.05.004_b0150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","article-title":"Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam\u2013pilot study","volume":"114","author":"Mundlamuri","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jocn.2021.05.004_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2017.05.001","article-title":"Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study","volume":"49","author":"Gujjar","year":"2017","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.jocn.2021.05.004_b0160","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jocn.2014.12.013","article-title":"Levetiracetam versus phenytoin in management of status epilepticus","volume":"22","author":"Chakravarthi","year":"2015","journal-title":"J Clin Neurosci"},{"issue":"11","key":"10.1016\/j.jocn.2021.05.004_b0165","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3109\/00207454.2015.1095743","article-title":"A comparison of four antiepileptic drugs in status epilepticus: experience from India","volume":"126","author":"Misra","year":"2016","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.jocn.2021.05.004_b0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2020.03.002","article-title":"Levetiracetam versus phenytoin for the treatment of established status epilepticus: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Li","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.jocn.2021.05.004_b0175","doi-asserted-by":"crossref","first-page":"107286","DOI":"10.1016\/j.yebeh.2020.107286","article-title":"Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: a systematic review and meta-analysis","volume":"111","author":"DeMott","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"10","key":"10.1016\/j.jocn.2021.05.004_b0180","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2013Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia."},{"key":"10.1016\/j.jocn.2021.05.004_b0185","doi-asserted-by":"crossref","unstructured":"Shorvon S, Sen A. What is status epilepticus and what do we know about its epidemiology?.Seizure.2020;75:131-136. DOI:10.1016\/j.seizure.2019.10.003.","DOI":"10.1016\/j.seizure.2019.10.003"},{"key":"10.1016\/j.jocn.2021.05.004_b0190","doi-asserted-by":"crossref","unstructured":"Nakamura K, Inokuchi R, Daidoji H, et al. Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. Medicine (Baltimore). 2017;96(25):e7206. DOI:10.1097\/MD.0000000000007206.","DOI":"10.1097\/MD.0000000000007206"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821002113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821002113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:29:36Z","timestamp":1760822976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821002113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":38,"alternative-id":["S0967586821002113"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.05.004","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the efficacy and safety of levetiracetam and phenytoin in the treatment of established status epilepticus: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}